Clinical trials: Rosuvastatin
Healthy Volunteers
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy…
- Trial name
- NCT07446400
- Testing
- Repinatrabit, EE/NE, Metformin
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dyslipidemia, Diabetes
Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes
- Trial name
- RAPID (NCT00526552)
- Where
- 3 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Healthy Volunteers
An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers
The purpose of this study is to evaluate the potential effect of bardoxolone methyl on the pharmacokinetics of digoxin and rosuvastatin and to assess the safety of the concomitant administration of bardoxolone methyl with digoxin…
- Trial name
- NCT01598363
- Testing
- Digoxin, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Male Subjects
Bioequivalence Study of CJ-30060 in Healthy Male Volunteers
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 10/160mg, Crestor® 20mg in healthy male volunteers.
- Trial name
- NCT03639493
- Testing
- Exforge® tab 10/160mg, Crestor® tab 20mg, CJ-30060 10/160/20mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
End-stage Kidney Disease, Diabetes Mellitus
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
Background Arteriovenous (AV) fistula is the most common vascular access for long-term hemodialysis in the end-stage renal disease (ESRD) patients. About 25% of these patients are diabetes mellitus.
- Conditions
- End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula
- Trial name
- NCT01863914
- Testing
- Rosuvastatin
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Statin, Aneurysm
Influence of Statins in Artery Aneurysms
The altered balance between the proteinases and their tissue inhibitors (TIMPS) is one of the pathogenetical mechanism of the aneurysmatic connective tissue degeneration.
- Conditions
- Statin, Aneurysm, Extracellular Matrix Alteration
- Trial name
- INSTANT (NCT03061487)
- Testing
- Open Surgical Treatment of Aneurysm (Aneurysmectomy)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Catanzaro
Cardiovascular Disorder, Diabetes Mellitus
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
The purpose of this study is to determine the efficacy of switching to a combination tablet ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose in those patients who have cardiovascular…
- Trial name
- NCT00862251
- Testing
- ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Dyslipidemia Associated With Type II Diabetes Mellitus
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C).
- Trial name
- NCT07359105
- Testing
- Moderate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
- Where
- 2 sites in South Korea
- Volunteers
- 2,186 people
- Sponsor
- Sin Gon Kim
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Stroke, Cognitive Decline
Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
This study is a phase III, prospective, placebo-controlled randomized clinical trial involving 8,518 subjects with low to moderate stroke risk, followed for 3 years in Brazil.
- Trial name
- PROMOTE (NCT05155137)
- Testing
- Drug Capsule (Valsartan + Amlodipine + Rosuvastatin), Stroke Riskometer
- Where
- 2 sites in Brazil
- Volunteers
- 8,518 people
- Sponsor
- Hospital Moinhos de Vento
Atherosclerosis Cardiovascular Disease
Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis
This study aims to compare the tolerability and metabolic safety of three low-dose statin/ezetimibe combinations (rosuvastatin/ezetimibe 2.5/10 mg, atorvastatin/ezetimibe 5/10 mg, pitavastatin/ezetimibe 1/10 mg) in patients with…
- Trial name
- MINI-STAR (NCT07871604)
- Testing
- Crezet 2.5/10mg, Litorvazet 5/10mg, Baroezet 1/10mg
- Where
- 2 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Healthy
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
- Trial name
- NCT00808678
- Testing
- ABT-143, ABT-335, rosuvastatin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hip Fracture
Statin in Hip Fracture
Statins (or HMG-CoA reductase inhibitors) have largely proven their efficacy in the primary and secondary prevention of cardiovascular events.
- Trial name
- STAFF (NCT01494090)
- Testing
- Rosuvastatin
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Brest
Type IIa and IIb Hypercholesterolaemia
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg.
- Trial name
- CAP-Chol (NCT00631189)
- Testing
- Rosuvastatin, Pravastatin, Atorvastatin
- Where
- 170 sites in France
- Volunteers
- 668 people
- Sponsor
- AstraZeneca
Atherosclerosis, Hypercholesterolemia
Rosuvastatin Affecting Aortic Valve Endothelium
Recent studies support the hypothesis that aortic stenosis (AS) develops due to atherosclerosis affecting the aortic valve endothelium.
- Trial name
- NCT00114491
- Testing
- Rosuvastatin
- Where
- Portugal
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hospital Pedro Hispano
Metabolic Syndrome
A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome
This is a Randomized, open-label, 2 groups, parallel design.
- Trial name
- NCT02968160
- Testing
- Telmisartan 40mg + Rosuvastatin 20mg, Telmisartan 80mg + Rosuvastatin 20mg, Telmisartan 40mg, 80 mg
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Yuhan Corporation
Rheumatoid Arthritis
Rosuvastatin in Rheumatoid Arthritis (RORA)
Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. The investigator's study is aimed at looking at the effects of proven cholesterol lowering treatment drug called rosuvastatin in rheumatoid…
- Trial name
- RORA (NCT00679510)
- Testing
- rosuvastatin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Dundee
Coronary Artery Disease
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
The study will assess the regression of yellow plaque content of the lipid pool after aggressive lipid therapy by utilizing NIR spectroscopy.
- Trial name
- YELLOW (NCT01567826)
- Testing
- standard of care lipid therapy, Aggressive lipid therapy
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Annapoorna Kini
Cardiovascular Diseases
Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin
This study is a multicenter, randomized, open-label, parallel, phase IV trial. The purpose of this study efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin.
- Trial name
- NCT04080310
- Testing
- Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
- Where
- 2 sites in South Korea
- Volunteers
- 270 people
- Sponsor
- Seoul National University Bundang Hospital